File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia

TitleClofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia
Authors
Tse, ELeung, AYHSim, JLee, HKKLiu, HSYYip, SFKwong, YL
KeywordsMedicine & Public Health
Hematology
Oncology
Issue Date2011
PublisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00277/index.htm
Citation
Annals Of Hematology, 2011, v. 90 n. 11, p. 1277-1281 How to Cite?
DOI: http://dx.doi.org/10.1007/s00277-011-1223-2
AbstractClofarabine (40 mg/m 2/day×5) and high-dose cytosine arabinoside (Ara-C, 1-2 g/m 2/day×5) were used in 10 men and 11 women, at a median age of 45 (22-62) years, with refractory (N=4) and relapsed (N=17) acute myeloid leukaemia, after a median of 3 (2-5) prior regimens. Grade 4 myelosuppression was observed in all cases, with two patients dying of bacterial sepsis. Nine patients achieved a complete remission. Disease status, number of prior therapies, and cytogenetic aberrations were not associated with the outcome. However, remission was only achieved with Ara-C at 2 g/m 2/day and not 1 g/m 2/day (9/15 versus 0/4, P=0.03). © Springer-Verlag 2011.
Persistent Identifierhttp://hdl.handle.net/10722/144875
ISSN
0939-5555
2023 Impact Factor: 3.0
2023 SCImago Journal Rankings: 0.912
ISI Accession Number ID
WOS:000296730300004
References
References in Scopus

 

DC FieldValueLanguage
dc.contributor.authorTse, Een_HK
dc.contributor.authorLeung, AYHen_HK
dc.contributor.authorSim, Jen_HK
dc.contributor.authorLee, HKKen_HK
dc.contributor.authorLiu, HSYen_HK
dc.contributor.authorYip, SFen_HK
dc.contributor.authorKwong, YLen_HK
dc.date.accessioned2012-02-21T05:43:42Z-
dc.date.available2012-02-21T05:43:42Z-
dc.date.issued2011en_HK
dc.identifier.citationAnnals Of Hematology, 2011, v. 90 n. 11, p. 1277-1281en_HK
dc.identifier.issn0939-5555en_HK
dc.identifier.urihttp://hdl.handle.net/10722/144875-
dc.description.abstractClofarabine (40 mg/m 2/day×5) and high-dose cytosine arabinoside (Ara-C, 1-2 g/m 2/day×5) were used in 10 men and 11 women, at a median age of 45 (22-62) years, with refractory (N=4) and relapsed (N=17) acute myeloid leukaemia, after a median of 3 (2-5) prior regimens. Grade 4 myelosuppression was observed in all cases, with two patients dying of bacterial sepsis. Nine patients achieved a complete remission. Disease status, number of prior therapies, and cytogenetic aberrations were not associated with the outcome. However, remission was only achieved with Ara-C at 2 g/m 2/day and not 1 g/m 2/day (9/15 versus 0/4, P=0.03). © Springer-Verlag 2011.en_HK
dc.languageengen_US
dc.publisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00277/index.htmen_HK
dc.relation.ispartofAnnals of Hematologyen_HK
dc.rightsThe Author(s)en_US
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.en_US
dc.subjectMedicine & Public Healthen_US
dc.subjectHematologyen_US
dc.subjectOncologyen_US
dc.subject.meshAdenine Nucleotides - administration & dosage - adverse effectsen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAntimetabolites, Antineoplastic - administration & dosage - adverse effectsen_HK
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - adverse effects - therapeutic useen_HK
dc.subject.meshArabinonucleosides - administration & dosage - adverse effectsen_HK
dc.subject.meshCytarabine - administration & dosage - adverse effectsen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLeukemia, Myeloid, Acute - drug therapy - prevention & controlen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshRecurrenceen_HK
dc.subject.meshRemission Inductionen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.subject.meshYoung Adulten_HK
dc.titleClofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemiaen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4551/resserv?sid=springerlink&genre=article&atitle=Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia&title=Annals of Hematology&issn=09395555&date=2011-11-01&volume=90&issue=11& spage=1277&authors=Eric Tse, Anskar Y. H. Leung, Joycelyn Sim, <i>et al.</i>en_US
dc.identifier.emailTse, E:ewctse@hku.hken_HK
dc.identifier.emailLeung, AYH:ayhleung@hku.hken_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.authorityTse, E=rp00471en_HK
dc.identifier.authorityLeung, AYH=rp00265en_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.description.naturepublished_or_final_versionen_US
dc.identifier.doi10.1007/s00277-011-1223-2en_HK
dc.identifier.pmid21455604-
dc.identifier.scopuseid_2-s2.0-84855196834en_HK
dc.identifier.hkuros207910-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84855196834&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume90en_HK
dc.identifier.issue11en_HK
dc.identifier.spage1277en_HK
dc.identifier.epage1281en_HK
dc.identifier.eissn1432-0584en_US
dc.identifier.isiWOS:000296730300004-
dc.publisher.placeGermanyen_HK
dc.description.otherSpringer Open Choice, 21 Feb 2012en_US
dc.identifier.scopusauthoridTse, E=7005019454en_HK
dc.identifier.scopusauthoridLeung, AYH=7403012668en_HK
dc.identifier.scopusauthoridSim, J=8501560000en_HK
dc.identifier.scopusauthoridLee, HKK=15136323100en_HK
dc.identifier.scopusauthoridLiu, HSY=8501559700en_HK
dc.identifier.scopusauthoridYip, SF=7102133678en_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK
dc.identifier.citeulike9128562-
dc.identifier.issnl0939-5555-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats